MDMA Superior to Placebo in Treatment of Severe PTSD

February 23, 2022 · Posted in Peer-Reviewed Published Data, Potential Treatments · Comment 
post traumatic stress disorder

An article by researcher Jennifer M. Mitchell and colleagues published in the journal Nature in 2021 reported that MDMA was more effective than placebo at treating severe post-traumatic stress disorder in an 18-week phase 3 clinical trial.

The article reported on a randomized, double-blind, placebo-controlled, multi-site trial that took place in the US, Canada, and Israel. Participants in the trial had severe PTSD, and in some cases also had dissociation, depression, a history of alcohol or substance use disorders, or childhood trauma. In the trial, 91 participants were required to stop any current psychiatric medications for a “washout” period, and then were randomized to either a group that received 12 therapy sessions plus placebo or a group that received 12 therapy sessions and 3 doses of MDMA, which were administered in a clinical setting.

Two months after the last therapy session, participants who had received MDMA during the trial showed greater reductions in PTSD symptoms and less functional impairment than those who were assigned to the placebo group during the trial. At the endpoint of the study, 67% of participants in the MDMA group no longer met the criteria for a PTSD diagnosis, compared to 32% of the placebo group.

Side effects that were more prevalent among the MDMA group were typically transient and mild to moderate in severity. These included muscle tightness, decreased appetite, nausea, sweating, feeling cold, and increased blood pressure and heartrate. The MDMA group did not show any increases in drug abuse or suicidality compared with the placebo group, and MDMA had similar effects among those participants with and without comorbid conditions. The authors concluded that MDMA was highly efficacious, safe, and well-tolerated as a treatment for PTSD and urged that further study of the treatment be done without delay.

Currently, US Food and Drug Administration (FDA)–approved treatments for PTSD include the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine, but approximately half of PTSD patients do not respond to these drugs or to evidence-based trauma-specific psychotherapy or cognitive-behavioral therapies. The FDA has designated MDMA-assisted therapy for PTSD a “Breakthrough Therapy.” This designation indicates that the therapy may be a substantial improvement over existing therapies for a serious condition, and is intended to speed up the drug development and review process.

MDMA (or 3,4-methylenedioxymethamphetamine) is the same chemical used recreationally under the name ecstasy or molly. However, the positive effects in the trial followed careful dosing (which is impossible with street drugs) and targeted therapy sessions.

We’re back!

February 23, 2022 · Posted in About the BNN · Comment 

After a pandemic-related hiatus, we’re back, and we hope to bring you articles regularly. For print subscribers, we hope to send out a single large issue in the coming months.